XML 103 R37.htm IDEA: XBRL DOCUMENT v3.24.0.1
SHARE-BASED PAYMENTS (Tables)
12 Months Ended
Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]  
Schedule of Deferred Compensation Arrangement with Individual, Share-Based Payments
The Company’s share-based compensation expense, by type of award, is as follows:
Years Ended December 31,
202320222021
RSUs(1)
$2,595 $2,244 $1,562 
SARs1,583 2,038 273 
Stock options447 359 323 
Total share-based compensation expense(2)
$4,625 $4,641 $2,158 
(1)The fair value of the RSUs granted under the Compensation Plan for the years ended December 31, 2023, 2022 and 2021 was estimated at the date of grant, using the stated market price on the NYSE American.
(2)Share-based compensation is recorded in Selling, general and administration in the Consolidated Statements of Operations and Comprehensive Income (Loss).
Share-Based Payment Arrangement, Restricted Stock Unit, Activity
A summary of the Company’s RSU unvested activity is as follows:
 Number of SharesWeighted Average Grant Date Fair Value
Unvested, December 31, 20201,094,056 $1.98 
 Granted441,241 3.89 
 Vested(635,233)1.94 
 Forfeited— — 
Unvested, December 31, 2021900,064 $2.94 
 Granted411,467 6.52 
 Vested(518,856)2.93 
 Forfeited(45,250)5.40 
Unvested, December 31, 2022747,425 $4.77 
 Granted450,232 7.36 
 Vested(448,883)4.24 
 Forfeited(106,935)7.03 
Unvested, December 31, 2023641,839 $6.57 
Share-Based Payment Arrangement, Stock Appreciation Right, Valuation Assumptions
The following table with the following weighted average assumptions used to determine fair values:
Years Ended December 31,
20232022
Risk-free interest rate3.58 %1.68 %
Expected life (in years)(1)
5.00 years4.98 years
Expected volatility(2)
55.00 %72.81 %
Expected dividend yield— %— %
Weighted average grant date fair value$3.45 $3.99 
(1)Monte Carlo analysis of SARs assumes employee suboptimal exercise at first vesting time for each tranche.
(2)Expected volatility is measured based on the Company’s historical share price volatility over a period equivalent to the expected life of the SARs.
Share-based Payment Arrangement, Stock Appreciation Right, Activity
A summary of the Company’s SARs activity is as follows:
 Number of SharesWeighted Average
Exercise Price
Weighted Average Remaining Contractual Life (Years)Intrinsic Value
Outstanding, December 31, 20201,720,623 $2.92 
 Exercised(48,201)2.92 
Outstanding, December 31, 20211,672,422 $2.92 
Granted833,315 6.47 
Exercised(6,730)2.92 
Forfeited(46,239)5.95 
Outstanding, December 31, 20222,452,768 $4.07 
 Granted308,333 7.36 
 Exercised(842,107)2.92 
 Forfeited(79,466)7.30 
 Expired— — 
Outstanding, December 31, 20231,839,528 $5.01 1.86$4,056
Exercisable, December 31, 2023250,036 $2.92 0.06$1,068
A summary of the Company’s unvested SARs activity is as follows:
 Number of SharesWeighted Average Grant Date Fair Value
Unvested, December 31, 20201,720,623 $1.25 
Granted— — 
Vested(1,147,074)1.27 
Forfeited— — 
Unvested, December 31, 2021573,549 $1.19 
Granted833,315 3.99 
Vested— — 
Forfeited(46,239)4.13 
Unvested, December 31, 20221,360,625 $2.81 
 Granted308,333 3.45 
 Vested— — 
 Forfeited(79,466)3.58 
Unvested, December 31, 20231,589,492 $2.89 
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions
The fair value of the stock options granted under the Compensation Plan is estimated at the date of grant, using the Black-Scholes Option Valuation Model, with the following weighted average assumptions:
Years Ended December 31,
202320222021
Risk-free interest rate3.98 %2.43 %0.44 %
Expected life (in years)3.2 years3.2 years5.0 years
Expected volatility(1)
74.00 %73.21 %61.96 %
Expected dividend yield— %— %— %
Weighted average grant date fair value$3.80 $4.93 $2.06 
(1)     Expected volatility is measured based on the Company’s historical share price volatility over a period equivalent to the expected life of the stock options.
Schedule of share-based compensation, stock options, activity
A summary of the Company’s stock option activity is as follows:
 Range of Exercise PricesNumber of SharesWeighted Average
Exercise Price
Weighted Average Remaining Contractual Life (Years)Intrinsic Value
Outstanding, December 31, 2020
$1.70 - $15.61
1,609,087 $2.91 
 Granted
3.89 - 8.41
169,310 3.99 
 Exercised
1.70 - 7.42
(775,814)2.95 
 Forfeited
1.76 - 5.91
(8,048)3.16 
 Expired
1.70 - 15.61
(51,653)8.14 
Outstanding, December 31, 2021
$1.70 - $8.41
942,882 $2.79 
 Granted
5.84 - 10.03
118,318 6.52 
 Exercised
1.70 - 5.46
(256,315)2.93 
 Forfeited
3.06 - 10.03
(20,700)5.91 
 Expired
1.76 - 5.18
(16,507)2.52 
Outstanding, December 31, 2022
$1.70 - $8.41
767,678 $3.24 
 Granted
5.34 - 8.60
153,299 7.20 
 Exercised
1.70 - 6.47
(348,538)2.83 
 Forfeited
3.89 - 7.36
(32,250)6.74 
 Expired
1.76 - 6.47
(16,720)3.75 
Outstanding, December 31, 2023
$1.76 - $8.60
523,469 $4.48 2.31$1,448
Exercisable, December 31, 2023
$1.76 - $8.41
354,286 $3.24 1.55$1,400
A summary of the Company’s unvested stock option activity is as follows:
 Number of SharesWeighted Average Grant Date Fair Value
Unvested, December 31, 2020403,990 $0.94 
 Granted169,310 2.06 
 Vested(351,934)1.23 
 Forfeited(8,049)1.60 
Unvested, December 31, 2021213,317 $1.34 
 Granted118,318 4.93 
 Vested(170,349)1.15 
 Forfeited(20,700)4.54 
Unvested, December 31, 2022140,586 $4.12 
 Granted153,299 3.71 
 Vested(92,453)3.57 
 Forfeited(32,250)3.78 
Unvested, December 31, 2023169,182 $4.11